TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01012661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse® Injectable Dermal Filler Mixed with Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse® Injectable Dermal Filler without Lidocaine
Description: Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
Study: NCT00603005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of TravAlert dosing aid with or without drop guider
Description: Each patient will use a dosing aid and/or drop guider for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of TravAlert dosing aid with or without drop guider
Description: Each patient will use a dosing aid and/or drop guider for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of TravAlert dosing aid with or without drop guider
Description: Each patient will use a dosing aid and/or drop guider for 6 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of TravAlert dosing aid with or without drop guider
Description: Each patient will use a dosing aid and/or drop guider for 6 months
Study: NCT04701125

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: selective head-neck cooling using PolarCap system
Description: Players receiving selective head-neck cooling after SRC
Study: NCT01898663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus-transfected DC + CIK
Description: Adenovirus-transfected autologous DC vaccine plus CIK cells
Study: NCT01128712

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: 150 mg /day

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: 450 mg/day
Study: NCT04740957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distal limb reintroduction of ileostomy effluent
Description: Patients will undergo water soluble contrast enema to confirm anastomotic healing 8 weeks post operatively as per standard practice at Imperial.~Patients will be educated in how to reintroduce ileostomy output to the distal (downstream) loop of their ileostomy. They will be asked to reintroduce 50ml of ileostomy output using a conventional long-tipped bladder syringe daily until surgery to close the stoma.
Study: NCT01065935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-RSV01
Description: Administered by nebulization once daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administered by nebulization once daily for 5 days
Study: NCT01477905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remi50 with prime
Description: for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remi20 with prime
Description: For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
Study: NCT03797560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin
Description: Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsule
Description: Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
Study: NCT02655146

Intervention type: DRUG
Group type: OTHER
Intervention: E2
Description: Patients will be on the Progynova tablets 4-10mg daily at least 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
Study: NCT02688374

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell
Study: NCT02655146

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin 3.75mg
Description: as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.

Intervention type: DRUG
Group type: OTHER
Intervention: triptorelin 3.75mg
Description: as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
Study: NCT00746408

Intervention type: OTHER
Intervention: Expert system guided tailored information
Description: The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.

Intervention type: OTHER
Intervention: Expert system guided tailored information
Description: The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
Study: NCT00101829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000 mg intravenous infusion
Study: NCT02688374

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment B: Nicotinell 2 mg coated mint gum
Description: Participants will be administered with 2 mg coated mint gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Description: Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
Study: NCT03857581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
Study: NCT02632838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iHealth BP7-Wireless Blood Pressure Wrist Monitor,
Description: The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
Study: NCT02251522

Intervention type: DEVICE
Intervention: ConforMIS Total Knee Replacement System
Description: Total knee replacement system using a patient specific implant.

Intervention type: DEVICE
Intervention: Off-the-Shelf Knee Replacement System
Description: Total knee replacement system not using a patient specific implant.
Study: NCT03716570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB054
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT02981355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microfracture treatment
Description: Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture treatment
Description: Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BST-CarGel
Description: BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
Study: NCT01701518

Intervention type: DRUG
Group type: OTHER
Intervention: Ozurdex
Description: biodegradable 0.7mg dexamethasone implant
Study: NCT00943943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily.
Study: NCT01574742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
Study: NCT04652739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene Softgel, 10 Mg
Description: Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).
Study: NCT02982278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Intervention under Nurse Guidance after Stroke
Description: CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Intervention under Nurse Guidance after Stroke
Description: CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
Study: NCT01449695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style counseling
Description: A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an individualized web portal
Description: This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an individualized web portal
Description: This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual and group consultations
Description: group consultations with peers and a nurse individual consultation with a nurse
Study: NCT01804985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
Study: NCT03065374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMM-529
Description: IMM-529

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT04438239

Intervention type: OTHER
Intervention: none, this study is observational
Description: none, this study is observational
Study: NCT03756259

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile Health (mHealth) for Pneumonia
Description: Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
Study: NCT04309981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult differentiated autologous T-cells with anti-BCMA specificity
Description: After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.
Study: NCT00064974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-5013
Description: CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
Study: NCT02738086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Change (PABC)
Description: Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Change (PABC)
Description: Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Change (PABC)
Description: Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Behavior Change (PABC)
Description: Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
Study: NCT03559491

Intervention type: DRUG
Intervention: Intravitreal injection
Description: Long term release steroid injection